Skip to main content

Cancer Liquid Biopsy Monitoring Study

Liquid biopsy is a test done on a sample of blood to examine pieces of DNA from tumor cells circulating in the blood (circulating tumor DNA, ctDNA). The detection of ctDNA in blood may be used to monitor treatment response, disease recurrence, and therapy resistance.

This study seeks to provide evidence that liquid biopsy monitoring provides useful genomic information for oncologists to improve how they treat their patients. Researchers at Sutter Health are collecting serial blood samples from eligible patients with newly diagnosed metastatic melanoma or metastatic lung cancer to monitor ctDNA mutations as participants undergo treatment. All participants will have results from ctDNA testing provided to their treating physicians.

Research topics

Related studies

View all studies
  • Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

  • A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

  • Molecular Characterization of Breast Cancer with Duct Forming Features

  • Research study

    DecisionDx-Melanoma Impact in Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes

  • Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?